Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.
about
Taurine: the appeal of a safe amino acid for skeletal muscle disorders(R,S)-2-chlorophenoxyl pyrazolides as novel substrates for improving lipase-catalyzed hydrolytic resolution.An optical assay of the transport activity of ClC-7.Intentional self-poisoning with the chlorophenoxy herbicide 4-chloro-2-methylphenoxyacetic acid (MCPA).ClC-1 chloride channels: state-of-the-art research and future challenges.CLC-K channels: if the drug fits, use it.Channel or transporter? The CLC saga continues.Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligandsNovel diuretic targetsIntegrin-targeted pH-responsive micelles for enhanced efficiency of anticancer treatment in vitro and in vivo.Molecular determinants of differential pore blocking of kidney CLC-K chloride channels.In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening.Alkaline pH block of CLC-K kidney chloride channels mediated by a pore lysine residue.Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1.Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels.Molecular Pharmacology of Kidney and Inner Ear CLC-K Chloride Channels.Mapping ligand binding pockets in chloride ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid.
P2860
Q26799770-987CFED4-9A29-4FA8-8725-5A30182ED206Q34052113-2D91B66A-D750-4CC8-A25A-82643DF5AC62Q34580197-640E7895-D65D-4882-9688-077EF5EB9713Q34667536-227FB7BC-3F7D-44D3-968D-E3C7D41CA7BAQ35541006-C121CFFC-1992-4A5A-B585-FE1D566BA35EQ35788147-7180632A-1700-4CBE-83AB-5E0516463C3EQ36265267-B0AEB81B-8353-45C2-9FBD-612806290A40Q36446249-9B2D9C89-6D14-4EE8-AF14-A6FD21C94F6BQ37234799-1595928D-C27C-4A32-90D4-0529BA63F4CEQ38562389-BD354E7E-3296-460F-A042-49566FC476E0Q40102720-F2ED6096-1AB2-4A09-A8BE-25188F588FEBQ41243043-997DB0E4-BEFB-4DDE-8629-05BB935E9F1CQ41282833-0FA8CF4B-C2FB-4721-8736-9C6A76A378FFQ42019489-98A2DF2A-9939-4F73-A9C5-4A0A6C560902Q42428797-386578C4-4CC2-4403-B331-5D3CE1424B4AQ42727743-390EFE0B-8185-4628-AC07-84C973241F6AQ52676150-DB338BE3-4474-49BB-A141-C06075CE972B
P2860
Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Molecular requisites for drug ...... henoxy-alkyl derivatives of 2-
@nl
Molecular requisites for drug ...... -chlorophenoxy)propionic acid.
@en
type
label
Molecular requisites for drug ...... henoxy-alkyl derivatives of 2-
@nl
Molecular requisites for drug ...... -chlorophenoxy)propionic acid.
@en
prefLabel
Molecular requisites for drug ...... henoxy-alkyl derivatives of 2-
@nl
Molecular requisites for drug ...... -chlorophenoxy)propionic acid.
@en
P2093
P50
P356
P1476
Molecular requisites for drug ...... -chlorophenoxy)propionic acid.
@en
P2093
Alessio Accardi
Fulvio Loiodice
Giuseppe Carbonara
Paolo Tortorella
Sonia Traverso
P304
P356
10.1124/MOL.62.2.265
P50
P577
2002-08-01T00:00:00Z